Department of Social and Behavioral Health News
Housed in the UNLV School of Public Health, the Department of Social and Behavioral Health consists of faculty who engage in research and develop and evaluate community-based programs that promote health and disease prevention. Our students learn to identify high-risk behaviors or trends in specific populations, as well as propose solutions that aim to improve overall public health in communities.
Current Social and Behavioral Health News
Public Health professor Gabriela Buccini and her team are studying the needs of mothers and children to help improve health outcomes for families.
Some of the most vibrant headlines featuring UNLV faculty and students.
Some of the biggest news headlines featuring UNLV faculty and students.
The top news stories starring university students and staff.
The top headlines featuring UNLV’s staff and students.
The students and faculty of UNLV are springing into headlines around the country.
Social and Behavioral Health In The News

Local advocacy group warns programs are already limited in Southern Nevada.
A recent landmark global analysis in The Lancet Public Health (2026), in which I was a senior collaborator, analyzed decades of data across 204 countries and revealed that while the global health workforce has grown to 122 million, women are driving the expansion of the world’s healthcare workforce (71.4%).
Nevada is making gains in offering afterschool programs addressing science, technology, engineering and math (STEM) learning, but more is needed especially to help rural areas, according to a study.
Coconut oil is a common edible oil used in the diet by certain populations around the world, including India. It is extracted from the kernel of mature coconuts harvested from the coconut palm.
Per- and polyfluoroalkyl substances are man-made chemicals used in the industry and consumer goods since the 1940s. These are often referred as “forever chemicals” because they do not break down easily in water, soil, or the human body.
Recent clinical trials from Merck and Moderna show promising results that a personalized messenger RNA (mRNA) melanoma vaccine intismeran autogene when combined with the immunotherapy drug pembrolizumab, can reduce the risk of melanoma recurrence or death by roughly 49% in high-risk patients after surgery compared to immunotherapy alone.
Social and Behavioral Health Experts